NASDAQ:IVVD Invivyd (IVVD) Stock Price, News & Analysis $1.32 +0.03 (+2.33%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.26▼$1.3350-Day Range$1.06▼$2.2552-Week Range$1.05▼$5.20Volume175,884 shsAverage Volume722,511 shsMarket Capitalization$157.50 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Invivyd alerts: Email Address Invivyd MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside758.6% Upside$11.33 Price TargetShort InterestBearish11.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 3 Articles This WeekInsider TradingSelling Shares$186,552 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.60) to $0.21 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.59 out of 5 starsMedical Sector502nd out of 936 stocksBiological Products, Except Diagnostic Industry74th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingInvivyd has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInvivyd has only been the subject of 1 research reports in the past 90 days.Read more about Invivyd's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.27% of the float of Invivyd has been sold short.Short Interest Ratio / Days to CoverInvivyd has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Invivyd has recently increased by 7.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInvivyd does not currently pay a dividend.Dividend GrowthInvivyd does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVVD. Previous Next 3.0 News and Social Media Coverage News SentimentInvivyd has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Invivyd this week, compared to 1 article on an average week.Search Interest3 people have searched for IVVD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Invivyd to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invivyd insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $186,552.00 in company stock.Percentage Held by Insiders17.90% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.36% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Invivyd's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Invivyd are expected to grow in the coming year, from ($0.60) to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invivyd is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invivyd is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvivyd has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Invivyd's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.Take these 4 steps to protect your retirement here. About Invivyd Stock (NASDAQ:IVVD)Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Read More IVVD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVVD Stock News HeadlinesJuly 1, 2024 | globenewswire.comInvivyd Announces its Addition to the Russell 2000® and Russell 3000® IndexesJune 14, 2024 | globenewswire.comInvivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 VariantsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 3, 2024 | globenewswire.comInvivyd to Participate at the Jefferies Global Healthcare ConferenceMay 31, 2024 | globenewswire.comInvivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal AntibodiesMay 31, 2024 | globenewswire.comInvivyd Announces the Appointment of Timothy Lee as Chief Commercial OfficerMay 29, 2024 | globenewswire.comInvivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)May 22, 2024 | globenewswire.comInvivyd Elects Two New Independent Members to its Board of DirectorsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 14, 2024 | markets.businessinsider.comStrong Buy Rating for Invivyd Amidst Potential EUA Approval and Promising Revenue ProjectionsMay 13, 2024 | msn.comInvivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call TranscriptMay 13, 2024 | globenewswire.comInvivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 12, 2024 | finance.yahoo.comWith 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interestMay 10, 2024 | finance.yahoo.comInvivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed AnalysisMay 9, 2024 | investorplace.comIVVD Stock Earnings: Invivyd Meets EPS for Q1 2024May 9, 2024 | globenewswire.comInvivyd Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 7, 2024 | globenewswire.comInvivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA FeedbackMay 2, 2024 | globenewswire.comInvivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business HighlightsSee More Headlines Receive IVVD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IVVD CUSIPN/A CIK1832038 Webadagiotx.com Phone781-819-0080FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Target$11.33 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+758.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-198,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.58% Return on Assets-79.93% Debt Debt-to-Equity RatioN/A Current Ratio5.77 Quick Ratio5.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book0.82Miscellaneous Outstanding Shares119,320,000Free Float97,958,000Market Cap$157.50 million OptionableOptionable Beta0.66 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Robert D. Allen Ph.D. (Age 55)Chief Scientific Officer Comp: $828.18kMs. Jill Andersen J.D. (Age 51)Chief Legal Officer & Corporate Secretary Comp: $931.68kMr. Jeremy Gowler (Age 47)Interim CEO, COO & Chief Commercial Officer Mr. William E. Duke Jr. (Age 52)M.B.A., Chief Financial Officer Ms. Stacy Price M.S. (Age 55)Chief Technology & Manufacturing Officer Scott YoungSenior Vice President of Investor Relations & Corporate CommunicationsMs. Julie Green M.B.A. (Age 49)Chief Human Resources Officer Ms. Heidi Spurling M.S.VP of Strategy & Operations and Chief of Staff to the CEODr. Mark A. Wingertzahn Ph.D. (Age 53)Senior Vice President of Clinical Development & Medical Affairs More ExecutivesKey Competitorsbluebird bioNASDAQ:BLUESeres TherapeuticsNASDAQ:MCRBKinnate BiopharmaNASDAQ:KNTEKronos BioNASDAQ:KRONiTeos TherapeuticsNASDAQ:ITOSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 239,373 shares on 7/26/2024Ownership: 0.201%SG Americas Securities LLCBought 25,201 shares on 7/12/2024Ownership: 0.032%Terrance McguireSold 112,381 sharesTotal: $186,552.46 ($1.66/share)Tidal Investments LLCBought 28,337 shares on 5/17/2024Ownership: 0.024%Bain Capital Life Sciences Investors LLCSold 137,612 shares on 5/16/2024Ownership: 1.508%View All Insider TransactionsView All Institutional Transactions IVVD Stock Analysis - Frequently Asked Questions How have IVVD shares performed this year? Invivyd's stock was trading at $3.94 on January 1st, 2024. Since then, IVVD stock has decreased by 66.5% and is now trading at $1.32. View the best growth stocks for 2024 here. How were Invivyd's earnings last quarter? Invivyd, Inc. (NASDAQ:IVVD) issued its earnings results on Thursday, May, 9th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.13. Who are Invivyd's major shareholders? Invivyd's top institutional investors include Bank of New York Mellon Corp (0.20%) and SG Americas Securities LLC (0.03%). View institutional ownership trends. How do I buy shares of Invivyd? Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IVVD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
